Senators and stakeholders are considering potential changes to the upper chamber's drug compounding bill -- particularly the bill's current pooling and repackaging definitions that stakeholders worry could bring home infusion providers under the new regulatory category for compounding manufacturers and increase the cost of certain eye treatment.
read here
No comments:
Post a Comment